With a robust background in technology and healthcare investments, the fund manager has successfully executed over 30 deals across North America and Europe. Their strategic focus on operator-first investments has led to notable exits in the biotech sector, demonstrating a strong emphasis on growth-stage opportunities. Leveraging data-driven insights, they have built a diverse portfolio that balances risk and innovation, aiming to capitalize on emerging market trends.